27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
The "Global Alpha-1 Antitrypsin Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The Global Alpha-1 Antitrypsin Drugs Market to grow at a CAGR of 10.64% during the period 2018-2022.
The report, Alpha-1 Antitrypsin Drugs Market 2018-2022 has been prepared based on an in-depth market analysis with inputs from industry experts. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers the revenue generated from the sales of alpha-1 antitrypsin drugs across the globe.
One trend affecting this market is strategic alliances and mergers. Companies are now working together in the form of collaboration or licensing for development of new drugs across location.
According to the report, one driver influencing this market is the improving diagnosis of alpha-1 antitrypsin deficiency. Detection is an important step in treating any disease or deficiency and several awareness programs have been conducted across the globe to recognize and differentiate alpha-1 antitrypsin deficiency from other diseases.
Further, the report states that one challenge affecting this market is the high cost of drugs. The high cost of alpha-1 antitrypsin therapies is responsible for impeding the market growth. The manufacture of plasma proteins is expensive and account almost four times the cost of manufacturing the pharmaceutical drugs.
Key vendors
- Shire
- CSL
- GRIFOLS
- Kamada
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: MARKET SEGMENTATION ROUTE OF ADMINISTRATION
- Segmentation by route of administration
- Comparison by Route of Administration
- Parenteral
- Inhalation
- Market opportunity by RoA
PART 08: CUSTOMER LANDSCAPE
PART 09: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas
- EMEA
- APAC
- Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 14: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- CSL
- GRIFOLS
- Kamada
- Shire
PART 15: PIPELINE ANALYSIS
- Pipeline analysis
PART 16: APPENDIX
For more information about this report visit https://www.researchandmarkets.com/research/249c2b/global_alpha1?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180827005513/en/
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!